ArtBlood Secures KRW 6.5 Billion in Series A for Synthetic Blood Production
ArtBlood, a Korean biotech startup specializing in the production of transfusion-grade blood, has successfully secured KRW 6.5 billion in its Series...
HEUNGKUK SECURITIES